- Trials with a EudraCT protocol (31,642)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (16,520)
31,642 result(s) found for: 0.
Displaying page 1,471 of 1,583.
EudraCT Number: 2012-001597-29 | Sponsor Protocol Number: HEM2012ZrOR001 | Start Date*: 2012-07-10 | |||||||||||
Sponsor Name:VU University Medical Center | |||||||||||||
Full Title: Tumor uptake of 89Zirconium-ofatumumab and 89Zirconium-rituximab in diffuse large B cell lymphoma patients | |||||||||||||
Medical condition: Diffuse large B cell lymphoma (DLBCL) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001963-25 | Sponsor Protocol Number: SNOXA12C701 | Start Date*: 2022-04-07 | |||||||||||
Sponsor Name:NOXXON Pharma AG | |||||||||||||
Full Title: An Open-label Phase 2 Study of Olaptesed Pegol (NOX-A12) Combined with Pembrolizumab and Nanoliposomal Irinotecan/5-FU/Leucovorin or Gemcitabine/nab-Paclitaxel inMicrosatellite-Stable Metastatic Pa... | |||||||||||||
Medical condition: Pancreatic cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004958-42 | Sponsor Protocol Number: MOM-M281-003 | Start Date*: 2019-01-11 | |||||||||||
Sponsor Name:Momenta Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Multicenter, Open-Label Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease ... | |||||||||||||
Medical condition: Early onset Severe Hemolytic Disease of the fetus and newborn (HDFN) | |||||||||||||
|
|||||||||||||
Population Age: In utero, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) NL (Completed) SE (Completed) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004860-36 | Sponsor Protocol Number: DEXAML-02 | Start Date*: 2018-05-15 | |||||||||||
Sponsor Name:French Innovative Leukemia Organization (FILO) | |||||||||||||
Full Title: A phase II study of dexamethasone added to induction and post-remission therapy in older patients with newly diagnosed AML. A French Innovative Leukemia Organization (FILO) study. | |||||||||||||
Medical condition: Elderly patients > 60 years with untreated acute myeloid leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003577-34 | Sponsor Protocol Number: 2022/702 | Start Date*: 2023-01-30 |
Sponsor Name:CHU de Besancon | ||
Full Title: Induction regorafenib in combination with metronomic cyclophosphamide, capecitabine and low-dose aspirin followed by chemotherapy in second line metastatic colorectal cancer. An open-label randomiz... | ||
Medical condition: cancer colorectal métastatique | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2014-001855-22 | Sponsor Protocol Number: M14AFS | Start Date*: 2015-01-14 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Netherlands Cancer Institute- Antoni van Leeuwenhoek Hospital | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Phase I/II study with the combination of afatinib and selumetinib in advanced KRAS mutant positive and PIK3CA wildtype non-small cell lung cancer and colorectal cancer | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Patients with histological or cytological proof of advanced KRAS mutant and PIK3CA wildtype non small cell lung cancer (NSCLC) and colorectal cancer (CRC). In part B: for which first-line treatment... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005740-27 | Sponsor Protocol Number: 2019/ABM/01/00081 | Start Date*: 2021-04-19 | |||||||||||
Sponsor Name:Uniwersytet Medyczny im. Piastów Śląskich we Wrocławiu | |||||||||||||
Full Title: Effect of Intravenous FERRic carboxymaltose on mortality and cardiovascular morbidity, and quality of life in iron deficient patients with recent myocardial infarction | |||||||||||||
Medical condition: Recent myocardial infarction associated with iron deficient | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005302-26 | Sponsor Protocol Number: DW.0701.005.2020P | Start Date*: 2023-01-05 | |||||||||||
Sponsor Name:John Paul II Hospital | |||||||||||||
Full Title: The effect of sacubitril/valsartan versus ramipril on left ventricular function and remodeling in patients with ischemic heart failure with mid-range ejection fraction | |||||||||||||
Medical condition: heart failure with moderately reduced ejection fraction (HFmrEF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003695-23 | Sponsor Protocol Number: 69HCL14-0201 | Start Date*: 2015-07-21 | |||||||||||
Sponsor Name:Hospices Civils de Lyon | |||||||||||||
Full Title: Phase II study evaluating the efficacy of aflibercept for the treatment of inflammatory choroidal neovascularization in young subjects: the ALINEA study | |||||||||||||
Medical condition: inflammatory choroidal neovascularization | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002265-36 | Sponsor Protocol Number: CHDR1518 | Start Date*: 2015-10-22 | ||||||||||||||||
Sponsor Name:Centre for Human Drug Research | ||||||||||||||||||
Full Title: A randomized, double blind, crossover, placebo controlled class-room experiment to assess the pharmacodynamics and pharmacokinetics of metoprolol in healthy volunteers with different polymorphism o... | ||||||||||||||||||
Medical condition: Influence of CYP2D6 polymorphism on metoprolol pharmacokinetics and pharmacodynamics in human volunteers | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000847-62 | Sponsor Protocol Number: ATI-450-PsA-201 | Start Date*: 2022-10-17 | |||||||||||
Sponsor Name:Aclaris Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Zunsemetinib vs Placebo in Patients with ... | |||||||||||||
Medical condition: Moderate-to-Severe Active Psoriatic Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000061-20 | Sponsor Protocol Number: 20322 | Start Date*: 2019-05-23 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Bayer AG | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: An open-label, multicenter rollover study to provide continued treatment with anetumab ravtansine for participants with solid tumors who were enrolled in previous Bayer-sponsored studies. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: FR (Completed) BE (Completed) PL (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-000424-19 | Sponsor Protocol Number: 213199 | Start Date*: 2020-09-07 | |||||||||||
Sponsor Name:Viiv Healthcare UK Limited | |||||||||||||
Full Title: A Phase IIIb, open-label, hybrid type III trial evaluating implementation strategies for long-acting cabotegravir plus long-acting rilpivirine every two months in HIV-1 infected, virologically su... | |||||||||||||
Medical condition: Human Immunodeficiency Virus Type 1 (HIV-1) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) NL (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012644-16 | Sponsor Protocol Number: 361/09 | Start Date*: 2009-07-24 | ||||||||||||||||
Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | ||||||||||||||||||
Full Title: PHASE 2 SINGLE- ARM STUDIES OF TEMOZOLOMIDE IN COMBINATION WITH TOPOTECAN IN REFRACTORY AND RELAPSED NEUROBLASTOMA AND OTHER PAEDIATRIC SOLID TUMOURS | ||||||||||||||||||
Medical condition: NEUROBLASTOMA AND OTHER PAEDIATRIC SOLID TUMOURS | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005569-14 | Sponsor Protocol Number: 80202135SLE2001 | Start Date*: 2021-08-24 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Nipocalimab in Adult Participants with Active Systemic Lupus Erythematosus | |||||||||||||
Medical condition: Active Systemic Lupus Erythematosus | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) PL (Completed) ES (Ongoing) BG (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000586-72 | Sponsor Protocol Number: NMSG#25/16 | Start Date*: 2017-10-10 | |||||||||||
Sponsor Name:Oslo University Hospital | |||||||||||||
Full Title: KRd consolidation in myeloma patients with a positive PET-CT after standard first line treatment. A phase II study | |||||||||||||
Medical condition: Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Trial now transitioned) DK (Trial now transitioned) SE (Prematurely Ended) PT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003039-20 | Sponsor Protocol Number: COMAN | Start Date*: 2014-11-28 | |||||||||||||||||||||
Sponsor Name:A. O. Istituti Ospitalieri di Cremona | |||||||||||||||||||||||
Full Title: RANDOMIZED PHASE II STUDY WITH SEQUENTIAL NON-CROSS RESISTANT CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED INOPERABLE OR METASTATIC GASTRO-ESOPHAGEAL ADENOCARCINOMA | |||||||||||||||||||||||
Medical condition: Locally advanced inoperable or metastatic gastro-esophageal adenocarcinoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005743-24 | Sponsor Protocol Number: 1214 | Start Date*: 2013-07-23 | |||||||||||
Sponsor Name:Centre Oscar Lambret | |||||||||||||
Full Title: ACTIVITY AND SAFETY OF REGORAFENIB IN PATIENTS WITH METASTATIC SOFT TISSUE SARCOMA PREVIOUSLY TREATED WITH ANTHRACYCLIN-BASED CHEMOTHERAPY: A MULTINATIONAL, RANDOMIZED, PHASE II, PLACEBO-CONTROLLED... | |||||||||||||
Medical condition: Metastatic soft tissue sarcoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001165-36 | Sponsor Protocol Number: FLORENCE_CC-486_HRMDS | Start Date*: 2020-10-27 | |||||||||||
Sponsor Name:Dipartimento di Medicina Sperimentale e Clinica- Università di Firenze | |||||||||||||
Full Title: A Phase 2, Monocentric, Pilot Study to evaluate safety and efficacy of CC 486 (Oral Azacitidine) Plus Best Supportive Care as maintenance of response to sc azacitidine in IPSS higher risk elderly M... | |||||||||||||
Medical condition: IPSS and IPSS-R higher Risk ( INT-2 and High risk IPSS; Intermediate, high and very high risk IPSS-R) elderly Myelodysplastic syndrome (MDS) patients | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004086-38 | Sponsor Protocol Number: ARGX-113-2002 | Start Date*: 2021-08-06 | |||||||||||
Sponsor Name:argenx BV | |||||||||||||
Full Title: A Long-Term, Single-Arm, Open-label, Multicenter Phase 3 Study to Evaluate the Safety and Tolerability of Multiple Subcutaneous Injections of Efgartigimod PH20 SC in Patients With Generalized Myast... | |||||||||||||
Medical condition: Generalized Myasthenia Gravis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) CZ (Completed) BE (Completed) NL (Completed) IT (Completed) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
